Focus on mibefradil: A novel selective T-type calcium channel blocker

Formulary

Volumn 32, Issue 11, 1997, Pages 1115-1133

  Dunn, Alisha ^a   Chow, Moses S S ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ASTEMIZOLE; CISAPRIDE; CYTOCHROME P450; DILTIAZEM; MIBEFRADIL; NIFEDIPINE; TERFENADINE;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; ARTERY DILATATION; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; DRUG EFFECT; DRUG ELIMINATION; EDEMA; ENZYME INHIBITION; HUMAN; HYPERTENSION; REVIEW; SYMPATHETIC TONE; VASCULAR SMOOTH MUSCLE;

EID: 0030718533     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Schmitt R, Kleinbloesem CH, Belz GG, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992;52:314-23.
2. Triggle DJ. Pharmacologic and therapeutic differences among calcium channel antagonists: Profile of mibefradil, a new calcium antagonist. Am J Cardiol 1996:78(Suppl 9A):7-12.
3. Portegies MCM, Schmitt R, Kraajj CJ, et al. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;18:746-51.
4. Clozel JP. Pharmacology of the new calcium antagonist mibefradil. J Cardiovasc Pharmacol 1996;27(Suppl A):S17-S21.
5. Posicor Product Information. Nutley, NJ: Roche Laboratories, Inc; June 1997.
6. Lacourcière Y, Poirier L, Lefebvre J, et al. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Am J Hypertens 1997;10:189-96.
7. Viskoper RJ, Bernink PJLM, Schelling A, et al. A randomized double-blind trial comparing mibefradil and amlodipine: Two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens 1997;11: 387-93.
8. Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: Fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 1996;38:273-90.
9. Massie BM, Chrysant SG, Jain A, et al. Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. Clin Cardiol 1997;20:562-8.
10. Bakx ALM, van der Wall EE, Braun S, et al. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J 1995;130: 748-57.
11. Véniant M, Clozel JP, Hess P, Wolfgang R. Hemodynamic profile of Ro 40-5967 in conscious rats: Comparison with diltiazem, verapamil, and amlodipine. J Cardiovasc Pharmacol 1991;18(Suppl 10): S55-S58.
12. Véniant M, Clozel JP, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991; 17:277-84.
13. Clozel JP, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol 1989:14:713-21.
14. Chapelle F, Stoleru L, Hayashida W, et al. RO40-5967, a new calcium antagonist profile: Bradycardia without myocardial depression? (abstract) Circulation 1994; 90(4 pt 2):139.
15. Bernink PJLM, Prager G, Schelling A, Kobrin I, on behalf of the Mibefradil International Study Group. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists? Hypertension 1996;27(part 1):426-32.
16. Data on file. Nutley, NJ: Roche Laboratories.
17. Alpert JS, Kobrin I, DeQuattro V, et al. Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris. Am J Cardiol 1997;79:1025-30.
18. Davies GJ, Tzivoni D, Kobrin I. Mibefradil in the treatment of chronic stable angina pectoris: Comparative studies with other calcium antagonists. Am J Cardiol 1997:80(4B):34C-39C.
19. Levine TB. The design of the Mortality Assessment in Congestive Heart Failure trial (MACH-1). Clin Cardiol 1997; 20:320-6.
20. Mulder P, Richard V, Compagnon P, et al. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997:29:416-21.
21. Muntinga HJ, van der Vring JAFM, Niemeyer MG, et al. Effect of mibefradil on left ventricular diastolic dysfunction in patients with congestive heart failure. J Cardiovasc Pharmacol 1996;27:652-6.
22. van der Vring JAFM, Bemink PJLM, van der Wall EE, et al. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure. Clin Ther 1996; 18:1191-206.